Statistics from Altmetric.com
Does dimebon improve cognitive function in people with mild to moderate Alzheimer’s disease?
183 people over 50 years of age with Alzheimer’s disease (DSM-IV and National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer’s Disease and Related Disorders criteria); Mini-Mental State Examination (MMSE) score 10–24; modified Hachinski ischaemic score ⩽4; and CT/MRI scan consistent with Alzheimer’s within 12 months prior to enrolment. Main exclusion criteria: potential other cause of dementia (eg, thyroid disease); cholinesterase inhibitor or N-methyl-D-aspartate receptor antagonist use within 60 days prior to enrolment; schizophrenia; stroke; Parkinson’s disease; seizure disorder; unstable medical illness; or hepatic/renal disease.
11 sites in Russia; recruitment September 2005–February 2006.
Dimebon (10 mg three times a day for 7 days, increased to 20 mg three times a day for the remainder of the study) or placebo for 26 weeks. Blinded treatment could be continued for an additional 26 week extension period if the participant agreed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.